The clinical value of p21(WAF1/CIP1) expression in superficial bladder cancer

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1173-1176

  Chow, Nan Haw ^a   Tzai, Tzong Shin ^a   Cheng, Hong Lin ^a   Liu, Hsiao Shen ^a   Chan, Shih Huang ^b   Tong, Yat Ching ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NONE

Author keywords

Bladder cancer; p21; p53; Prognosis; Superficial tumors

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SUPERFICIAL CANCER; ADULT; AGED; BLADDER TUMOR; DISEASE COURSE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TIME;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0033625688     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Heney NM, Ahmed S, Flanagan MJ, et al: Superficial bladder cancer: progression and recurrence. J Urol 130: 1083-1086, 1983.
2. Lipponen PK, Eskelinin MJ, Kiviranta J, et al: Prognosis of transitional cell bladder cancer: a multivariate prognostic score for improved prediction. J Urol 146: 1535-1540, 1991.
3. Kiemeney LA, Witjes JA, Heijbroek RP, et al: Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150: 60-64, 1993.
4. Holmang S, Hedelin H, Anderstrom C, et al: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153: 1823-1827, 1995.
5. Marx J: How p53 suppress cell growth. Science 262: 1644-1645, 1993.
6. Sidransky D, von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709, 1991.
7. Esrig D, Spruck CH III, Nichols PW, et al: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397, 1993.
8. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53-59, 1993.
9. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264, 1994.
10. Serth J, Kuczyk MA, Bokemeyer C, et al: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71: 201-205, 1995.
11. Chen YQ, Cipriano SC, Arenkiel JM, et al: Tumor suppression by p21WAF1. Cancer Res 55: 4536-4539, 1995.
12. El-Deiry WS, Harper JW, O'Connor PM, et al: WAF1/CIP1 is induced in p53- mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
13. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinase. Nature 366: 701-707, 1993.
14. Steinman RA, Hoffman B, Iro A, et al: Induction of p21(WAF-1/CIP1) during differentiation. Oncogene 9: 3389-3396, 1994.
15. Michiel P, Chedid M, Lin D, et al: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
16. Johnson M, Dimitrov D, Vojta PJ, et al: Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 mRNA in human cells. Mol Carcinogenesis 11: 59-64, 1994.
17. Sheikh MS, Li SX, Shao ZM, et al: Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma:role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3414, 1994.
18. WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with Bacillus Calmetter-Guerin intravesical therapy. J Urol 161: 621-628, 1999.
19. Komiya T, Hosono Y, Hirashima T, et al: p21 expression as a predictor for favorable prognosis in squamous cell carcinoma. Clin Cancer Res. 3: 1831-1835, 1997.
20. Matsushima H, Sasaki T, Goto T, et al: Immunohistochemical study of p21 WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 29: 778-783, 1998.
21. WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90: 1072-1079, 1998.
22. Ohono A, Hirashima T, Kubo A, et al: p53 status and prognosis in I-IIIa non-small cell lung cancer. Int J Oncol 10: 521-528, 1997.
23. Marchetti A, Doglioni C, Barbareschi M, et al: p21 RNA, and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumor differentiation. Oncogene 12: 1319-1324, 1996.
24. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281-5285, 1997.
25. Cote RJ, Dunn MD, Chatterjee SJ, et al: Elevated dn absent pRb expression is associated with bladder cancer progression and has cooperative efffects with p53. Cancer Res 58: 1090-1094, 1998.
26. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57: 1217-1221, 1997.
27. Grossman HB, Liebert M, Antelo M, et al: p63 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4: 829-834, 1998.
28. Tetu B, Allard P, Fradet Y, et al: Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary superficial bladder cancer. Human Pathol 27: 922-926, 1996.
29. Sidransky D, Frost P, Von Eschenbach A, et al: Clonal origin of bladder cancer. N Engl J Med 326: 737-740, 1992.